Evaluation of liraglutide in the treatment of Alzheimer's disease

Edison, Paul; Daniela Femminella, Grazia; Ritchie, Craig; Holmes, Clive; Walker, Zuzana; H. Ridha, Basil; Raza, Sanara; R Livingston, Nicholas; Nowell, Joseph; Busza, Gail; Frangou, Eleni; Love, Sharon; Williams, Gareth; M. Lawrence, Robert; McFarlane, Brady; Archer, Hilary; Coulthard, Elizabeth; R. Underwood, Benjamin; Koranteng, Paul; Karim, Salman; Bannister, Carol; Perneczky, Robert; Prasanna, Aparna; Junaid, Kehinde; McGuinness, Bernadette; Nilforooshan, Ramin; Macharouthu, Ajayverma; Donaldson, Andrew; Thacker, Simon; Russell, Gregor; Malik, Naghma; Mate, Vandana; Knight, Lucy; Kshemendran, Sajeev; Hölscher, Christian; Mansouri, Anita; Chester‐Jones, Mae; Holmes, Jane; Williams, Steven; J. Brooks, David; Harrison, John; Tadros, George; Peter Passmore, Anthony; Ballard, Clive

doi:10.1002/alz.057848

Public

Evaluation of liraglutide in the treatment of Alzheimer's disease

Published in Alzheimer s & Dementia • Dec 1, 2021

Authors:

Paul Edison

Grazia Daniela Femminella

Craig Ritchie

Abstract

Abstract Background Liraglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue licensed for the treatment of type 2 diabetes. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic p...

Subject

Liraglutide

Medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!